A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 5,67 (+138,24%). A mediana é € 5,44 (+128,57%).
| Comprar |
11 |
| Manter |
3 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Ovid Therapeutics unveils pipeline strategy for neuronal hyperexcitability and KCC2 platform
Ovid Therapeutics presented at the H.C. Wainwright conference its focus strategy on brain disorders driven by neuronal hyperexcitability, centered on two lead programs: OV329 for epilepsy and OV4071, the first oral direct KCC2 activator. Management said OV329 shows a strong safety profile and is expected to report photosensitivity data in the coming months and phase II results in about a year; OV4071 is in phase I, a ketamine challenge is planned before year‑end, and a phase II program for acute schizophrenia is scheduled for mid‑2025. Financial figures were not discussed; management emphasized the platform ambitions, biomarker‑driven development and multiple near‑term proof‑of‑concept catalysts. » Mais em de.investing.com
Ovid Therapeutics emphasizes KCC2 program and epilepsy pipeline as value drivers
At the Cantor conference Ovid Therapeutics presented its two‑pillar strategy centered on the KCC2 program (OV4071) and the epilepsy pipeline (notably OV329), and views KCC2 as the main long‑term value driver if early human data confirm preclinical results. OV4071 is in phase I; a ketamine challenge and several biomarker studies are intended to link earlier animal data with human data. OV329 is being positioned to differentiate in focal-onset and pediatric epilepsies; proof‑of‑concept data and a phase II are planned for 2024/2025. Ovid also retains rights to milestone/license payments from Soticlestat, which represents additional upside without development risk. » Mais em de.investing.com
Ovid Therapeutics names Kevin Norrett chief business officer, promotes key executives
Ovid Therapeutics appointed Kevin Norrett as chief business officer to lead business development and strategic partnerships. Charles Carter was promoted to CFO, succeeding Jeffrey Rona who will remain a long-term advisor through 2027, and Victoria Fort was promoted to chief strategy officer. The company reported Q1 EPS of (12c), said development programs are on track, and expects to be well capitalized into 2029. » Mais em finance.yahoo.com
Ovid Therapeutics appoints Kevin Norrett as chief business officer and restructures leadership team
Ovid Therapeutics brings in Kevin Norrett as chief business officer to lead business and corporate development and strategic partnerships. Charles Carter was promoted to chief financial officer; Jeffrey Rona will remain on board as an advisor through 2027. Eliseo Salinas joins as executive R&D advisor and Victoria Fort was promoted to chief strategy officer; Fort led financing rounds that secure the company’s cash runway through 2029. The company is developing, among others, OV329 for treatment-resistant focal-onset seizures and OV4071 for central nervous system disorders. » Mais em de.investing.com
Ovid Therapeutics appoints Dr. Anna Greka to board and creates science and technology committee
Ovid Therapeutics has appointed Dr. Anna Greka to its board effective June 15, 2026; she will chair the newly formed Science and Technology Committee and join the Compensation Committee. Dr. Greka is head of Ladders to Cures, a Core Institute member at the Broad Institute, a professor at Harvard Medical School, and has founded and advised several biotech companies. The announcement comes after the stock rose more than 700% over the past year; Ovid is developing, among other programs, OV329 for treatment-resistant focal onset seizures and additional KCC2 activators. » Mais em de.investing.com
Dados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 0 | 100,00% |
| Ganho bruto | 0 | 100,00% |
| Ganho líquido | -18,35 mi | 77,08% |
| EBITDA | -18,05 mi | 74,42% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 435 mi |
Número de ações | 188,73 mi |
Máximo/mínimo de 52 semanas | € 2,82 - € 1,07 |
| Dividendos | Não |
Beta | 0,24 |
PER (PE Ratio) | -6,20 |
PEG (PEG Ratio) | 0,21 |
P/VC (PB Ratio) | 2,60 |
P/V (PS Ratio) | 330,38 |
Perfil da empresa
A Ovid Therapeutics Inc., uma empresa biofarmacêutica, desenvolve medicamentos com impacto para doentes e famílias com perturbações neurológicas nos Estados Unidos. A empresa está a desenvolver o OV101, um candidato a fármaco, que se encontra em ensaios clínicos de Fase 2A para o tratamento da síndrome do X frágil; o OV329, um inibidor da GABA aminotransferase para o tratamento de convulsões associadas à esclerose tuberosa e aos espasmos infantis; e o OV350, uma molécula pequena para o tratamento de epilepsias. Desenvolve ainda o OV882, uma terapia génica de ARN em forma de gancho curto (shRNA) para o tratamento da síndrome de Angelman; e o OV815 para o tratamento de perturbações neurológicas associadas à família de proteínas das cinesinas. A empresa tem acordos de licenciamento e colaboração com a Healx, a AstraZeneca AB, a H. Lundbeck A/S e a Northwestern University, bem como com a Marinus Pharmaceuticals, Inc. A empresa foi constituída em 2014 e tem a sua sede em Nova Iorque, Nova Iorque.
| Nome | OVID THERAPEUTICS DL-,001 |
| CEO | Margaret Alexander |
| Sede | New York City,
ny EUA |
| Site | |
| Setor | Materiais básicos |
| Indústria | Produtos químicos |
| Entrada em bolsa | 05/05/2017 |
| Colaboradores | 23 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | OVID |
Frankfurt | 1OT.F |
Düsseldorf | 1OT.DU |
München | 1OT.MU |